SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending due to discussions around a potential short squeeze and recent volatility, sparked by news of their expansion into menopause treatments. The stock's price action is seeing a lot of back and forth between bulls and bears. Some traders point to the potential for further gains, while others cite concerns about valuation and management actions.

Aventus Network

Aventus Network ($AVT) is trending, with community members expressing excitement about its potential, particularly its Aventus Cloud service. Discussion includes its interoperability with Polkadot and Ethereum, as well as its listing on Coinbase. Some users believe $AVT is undervalued and poised for significant growth.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to levels not seen in over a decade, driven by a potential short squeeze and global demand for bullion. Community discussions revolve around whether the rally is sustainable, with some citing supply shortages and a potential for further gains, while others warn of a possible pullback. The broader context includes concerns about the dollar and traditional safe haven assets.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as investors discuss its potential in the evolving app store landscape, particularly following recent rulings impacting Google's Play Store policies. Community members are speculating on how the company might capitalize on these changes and forge new partnerships, with some drawing comparisons to the AI-driven growth of companies like Applovin. Bullish sentiment is building amidst discussions of potential short squeezes and a multi-year uptrend.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending following news of FDA fast track designation, sparking significant community discussion and a surge in price and volume. Traders are pointing to technical indicators and potential short squeezes, while analysts have increased price targets. The community is actively debating potential breakout levels and the stock's overall potential in the biotherapeutics space.

Aptera Motors Corp. is an automotive technology company focused on the development, production, and distribution of energy-efficient, solar-powered, battery-electric vehicles. Its flagship product, the Aptera, is a three-wheeled, two-seat solar vehicle designed to reduce reliance on traditional charging by utilizing integrated solar panels. The company was founded by Steve Fambro and Chris Anthony and is headquartered in San Diego, CA.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending due to high volatility following its direct listing, with community members actively discussing trading halts and potential market manipulation.  While some investors express excitement about the company's solar EV technology and pre-order demand, others voice concerns about production timelines and the vehicle's design.  The stock's extreme price fluctuations have fueled speculation about short squeezes and long-term potential within the EV sector.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is surging, fueled by safe-haven demand amid economic uncertainty and global dissatisfaction. The community is debating whether this rally signals a blow-off top or a continuation of the upward trend, with some expressing concerns about overbought conditions and potential pullbacks. Discussions also revolve around the interplay between gold, the dollar, and potential shifts in global economic power.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending due to investor reactions to its AI strategy and cloud infrastructure spending, particularly after the company's AI World event. While some analysts are optimistic about long-term revenue potential, the community is concerned about near-term profitability, rising debt, and heavy capital expenditure, leading to a sell-off despite positive AI cloud deals.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab ($GTLB) is trending amid takeover speculation, with Datadog ($DDOG) and Google ($GOOGL) mentioned as potential acquirers and a possible bidding war. The community is weighing the potential deal price, with some focusing on a $50 breakout level while others suggest a price above $60 per share is more realistic. Despite the takeover buzz, some traders dismiss the rumors and express concern about the stock's performance.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

CVM is trending as investors await a potential decision from the Saudi Food and Drug Authority (SFDA) regarding Cel-Sci's application for Breakthrough Medicine Designation for Multikine. Community members are debating the timeline for the SFDA's decision and its potential impact, with some expressing skepticism towards the CEO's statements, while others highlight the partnership with Dallah Pharma and potential for commercialization in Saudi Arabia.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The National Highway Traffic Safety Administration (NHTSA) announced on Monday that it has closed its investigation into approximately 24,000 model year 2017-2018 Alfa Romeo Giulia vehicles.The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures in certain Alfa Romeo Giulia vehicles. During its investigation, the NHTSA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24003-86036.pdf">determined</a> that the vehicles were equipped with fuel delivery pumps supplied by Vitesco Technologies Germany GmbH.However, Stellantis issued a recall earlier this month covering 29,467 model-year 2017–2019 Alfa Romeo Giulia vehicles and 24,382 model-year 2018 Alfa Romeo Stelvio vehicles, all equipped with the suspect Vitesco fuel delivery pump. A remedy is under development, the company said.The NHTSA stated that it is closing its probe in light of the recall issued by Stellantis. However, the regulator said it reserves the right to take additional action if warranted.The NHTSA also noted that it is aware of 1,900 vehicles experiencing failures related to the issue, adding that it is aware of one crash associated with the issue, but no injuries, fatalities, or fires.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> remained within ‘bearish’ territory while message volume remained at ‘high’ levels.The NHTSA also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24006-86034.pdf">announced </a>on Monday that it has closed a probe into 226,250 model year 2018-2020 Dodge Journey vehicles, which was initiated in February 2024 due to complaints regarding the backup camera function. The company recently issued a recall to resolve the issue and noted that it will replace defective cameras in the recalled vehicles with an updated part that resolves the problem.STLA stock is down 29% this year and approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Alfa Romeo Giulia on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles

The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures. 

Equity

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

EA Series Trust - Altrius Global Dividend ETF

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

DIVD
EA Series Trust - Altrius Global Dividend ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DIVD News

DIVDEA Series Trust - Altrius Global Dividend ETF